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ABSTRACT 
 
A large fraction of the sequence variants of unknown significance or unclassified variants 
(UVs), including exonic variants, could be pathogenic by affecting mRNA splicing. The 
breast and ovarian cancer susceptibility gene BRCA1 exhibits a large spectrum of sequence 
variation but only two variants, both located in exon 18, have been shown experimentally to 
affect splicing regulatory elements. In the present study, we investigate the impact on splicing 
of the variant BRCA1 c.5434C>G (p.Pro1812Ala), identified in an ovarian cancer patient. 
This variant has previously been studied at the protein level with inconclusive results 
concerning its pathogenic role. Here, we show, using patient RNA analyses and hybrid 
minigene assays, that this variant induces a major splicing defect, with skipping of exon 23, 
resulting in frameshift and predicted protein termination within the second BRCT domain. 
This argues for its classification as a pathogenic splicing mutation. Moreover, we 
demonstrate, using an exonic splicing enhancer-dependent minigene assay, that the segment 
c.5420-5449 of BRCA1, in the centre of exon 23, exhibits splicing enhancer properties. This 
enhancement is abolished by the c.5434C>G mutation, indicating that the nucleotide change, 
in this highly conserved region, affects a splicing regulatory element. Bioinformatics analyses 
predict that the mutation c.5434C>G creates an hnRNPA1-dependent splicing silencer. These 
results also suggest that UVs in highly conserved nucleotide sequences of short exons may be 
good candidates for detecting functionally relevant splicing regulatory elements.  
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INTRODUCTION 
Genetic counseling is often limited by lack of knowledge about the pathogenic role of 
a large fraction of germline sequence variations. These are usually referred to as variants of 
unknown significance or unclassified variants (UVs). These types of variants are especially 
problematic for the breast and ovarian cancer susceptibility gene, BRCA1, which exhibits a 
large spectrum of sequence variation. Among these variants, most of the missense changes 
identified in the BRCA1 gene, as well as many intronic sequence changes, are currently listed 
as UVs in the database of the Breast Cancer Information Core (BIC, 
http://research.nhgri.nih.gov/projects/bic).   
Over the past ten years, it became clear that a large fraction of missense UVs could be 
deleterious by impacting pre-mRNA splicing.[1,2] Exonic mutations alter either splice site 
sequences or splicing regulatory elements such as ESE (exonic splicing enhancer) or ESS 
(exonic splicing silencer). Most ESE elements promote exon inclusion by interacting with 
activating splicing factors, usually members of the serine/argine-rich protein family. In 
contrast, ESS elements play a role in splicing repression usually through the binding of 
proteins, mostly belonging to the heterogenous nuclear ribonucleoprotein (hnRNP) family. 
Mutations in these cis-acting elements may induce abnormalities in pre-mRNA splicing, that 
could result either in the degradation of the mature aberrant mRNA by the nonsense mediated 
decay (NMD) pathway or in the production of an altered protein.[3] 
Here, we describe the characterization of the c.5434C>G (p.Pro1812Ala) variant 
found in the BRCA1 gene in a French ovarian cancer patient. This variant was previously 
identified in several families with breast and/or ovarian cancers and was reported as an UV 
but was not listed in the BIC database of BRCA mutations.[4-6] Because it co-segregates with 
the high risk phenotype at least in one family,[6] this variant was suspected to be deleterious. 
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It was initially thought that it could interfere with the activity of the BRCA1 protein, 
considering the high degree of conservation across species of the proline at position 1812 and 
its location in the second BRCT (BRCA1 carboxyl terminal) domain. However, a previous 
study showed that the BRCA1 p.Pro1812Ala variant induces a modest decrease in the activity 
of the BRCA1 protein, based on a transcriptional transactivation assay.[6] More recently, the 
effects of this variant were also tested on structural integrity, protein stability and interaction 
with various phosphopeptides but these data were not sufficient to characterize this mutation 
as pathogenic.[7] Thus, the deleterious nature of this missense mutation was unclear at the 
protein level and this uncertainty prompted us to investigate its impact on pre-mRNA 
splicing. Here, we show that the BRCA1 c.5434C>G variant induces a major splicing defect, 
resulting in skipping of exon 23.  
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METHODS 
Patient 
The BRCA1 c.5434C>G variant tested in this study was detected in an index case selected 
from families undergoing genetic counseling in the Western French breast cancer genetics 
network. The criteria for diagnostic mutation screening of BRCA1/2 genes in patients were 
according to the current French recommendations. The patient gave signed informed consent. 
 
Nomenclature 
The DNA sequence numbering is based on the cDNA sequence for BRCA1 (NCBI RefSeq 
NM_007294), following the recommendations of the Human Genome Variation Society 
(HGVS, first position of the translation initiation codon ATG=1).  
 
Genetic analysis 
Patient peripheral blood samples were collected in EDTA tubes. Genomic DNA was isolated 
using an automated procedure (EZ1 DNA blood kit on biorobot EZ1 workstation, Qiagen, 
Hilden, Germany).  Screening for BRCA1 and BRCA2 mutations was performed using 
denaturing High Performance Liquid Chromatography (dHPLC) or High Resolution Melting 
(HRM), followed by direct sequencing. Screening for BRCA1 and BRCA2 large 
rearrangements was performed using a combination of the multiplex ligation-dependent probe 
amplification (MLPA) and quantitative multiplex PCR of short fluorescent fragments 
(QMPSF) methods.  
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RT-PCR analysis of patient blood RNA 
Whole blood samples were collected from patients and voluntary healthy donors in PAXgene 
Blood RNA tubes (Qiagen). RNA extraction was performed according to the manufacturer’s 
protocols, including DNase treatment. RT-PCR was performed from 250 ng of total RNA, a 
forward primer complementary to BRCA1 exon 20 (5’-GAAGAAACCACCAAGGTCCAA-
3’) and a reverse primer complementary to BRCA1 3’UTR (5’-
GAAGAGTGAGAGGAGCTCCCAG-3’), using one-step RT-PCR kit (Qiagen). All 
amplifications were performed using a touch-down PCR program. The thermocycler 
parameters for the RT-PCR were 50°C for 30 minutes for the reverse transcription step, 95°C 
for 15 minutes for the initial DNA polymerase activation, 26 cycles of 94°C for 40 seconds, 
63°C for 1 minute with a decrease of 0.5°C/cycle, and 72°C for 45 seconds, followed by 26 
cycles of: 94°C for 40 seconds, 50°C for 20 seconds and 72°C for 45 seconds, and a final 
extension at 72°C for 10 minutes. RT-PCR was also performed using a total of 40 and 46 
cycles. RT-PCR products were separated by electrophoresis on a 0.8% agarose gel containing 
ethidium bromide and visualized by exposure to ultraviolet light. Semi-quantitative analysis 
of the RT-PCR products was carried out using a Gel docTM XR 170-8170 instrument (Biorad) 
and the software Quantity One (Biorad). RT-PCR products were purified and sequenced using 
a cycle sequencing reaction kit (Big Dye Terminator kit v1.1, Applied Biosystems) on an 
automated sequencer (ABI 3130, Applied Biosystems). 
 
Bioinformatics predictions of splicing alterations 
Exonic variants were analyzed for possible splicing enhancer (ESE) alteration with ESEfinder 
3.0 (http://rulai.cshl.edu/cgi-bin/tools/ESE3/esefinder.cgi) [8, 9] and RESCUE-ESE 
(http://genes.mit.edu/burgelab/rescue-ese) [10] using the integrated software Alamut 
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(Interactive Biosoftware, http://www.interactive-biosoftware.com) and Human Splicing 
Finder 2.4 (http://www.umd.be/HSF).[11]  Exonic variants were also analyzed for possible 
splicing silencer (ESS) creation using Human Splicing Finder 2.4. 
 
Splicing minigene reporter assay 
Generation of minigene constructs. The splicing minigene assay has been previously 
described.[12-14] Wild-type and mutant c.5434C>G BRCA1 exon 23, together with 236 bp of 
the 5’ flanking intron and 202 bp of the 3’ flanking intron, were amplified by PCR using 
forward primer (5’-GACCAGATCTATTAGCCAGGGGTGGTGGTA-3’) and reverse primer 
(5’-GACCACGCGTCACCCCATGGAAACAGTTCA-3’), carrying 5’ tails with BglII and 
MluI restriction sites (underlined), respectively. After digestion with BglII and MluI, the PCR 
products were inserted into the intron of the two-exons pCAS1 splicing reporter minigene 
vector (Fig. 1B).[12-14] 
Transfection and RT-PCR analysis. After identification by plasmid sequencing, the wild-type 
and mutant minigene constructs were transiently transfected into HeLa cells using FuGENE 6 
transfection reagent, according to manufacturer’s instructions (Roche Applied Science). Cells 
were then collected 24 h post-transfection. Total RNA was extracted using the TriPure 
Isolation Reagent (Roche Applied Science) and analyzed by RT-PCR. The reverse 
transcription (RT) step was performed using the Superscript II reverse transcriptase 
(Invitrogen) primed with oligod(T)18 (New England Biolabs). The resulting cDNA was 
amplified by PCR (25, 30, 35 cycles) using the forward primer F (5’-
CTCCGCAGGTCCGCT-3’) and the reverse primer R (5’-
ATTGGTTGTTGAGTTGGTTGTC-3’) (Fig. 1B). RT-PCR products were separated by 
electrophoresis on 2.5% agarose gel containing ethidium bromide and visualized by exposure 
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to ultraviolet light. Semi-quantitative analysis of the RT-PCR products was carried out using a 
Gel docTM XR 170-8170 instrument (Biorad) and the software Quantity One (Biorad). Each 
DNA band was gel-extracted using Nucleospin Extract II kit (Macherey-Nagel) and 
sequenced using Big Dye Terminator cycle sequencing kit (Applied Biosystems) on an 
automated sequencer (ABI 3130, Applied Biosystems). 
 
ESE-dependent splicing assay 
Generation of pcDNA-Dup constructs. BRCA1 exon 23 wild-type fragment c.5420-5449 was 
tested for the presence of ESE splicing regulatory sequences by using an ESE-dependent 
splicing assay.[12] Briefly, the exonic fragment was obtained by annealing complementary 
5’-phosphorylated oligonucleotides designed to encompass 30 nucleotides around the 
mutation position and to carry 5’-EcoRI and 3’-BamHI compatibles ends (Fig. 3A). This 
duplex was inserted into the EcoRI and BamHI sites of the pcDNA-Dup plasmid. This 
expression vector contains a splicing cassette consisting of a β-globin-derived three-exon 
minigene (Dup) under the control of the cytomegalovirus (CMV) promoter (Fig. 3A).[12] The 
effects of the mutations BRCA1 c.5434C>G and c.5434C>T were tested in parallel in the 
ESE-dependent splicing assay. Control experiments were performed, as previously 
described,[12] using pcDNA-Dup derived minigenes, including i) the empty pcDNA-Dup 
plasmid, ii) the pcDNA-Dup-BR2Int11 construct which contains a fragment without known 
regulatory elements (5’-TGTTGTCCAGGTCACATTCAATAG-3’) derived from BRCA2 
intron 11 and iii) the pcDNA-Dup-SF2/ASF-3x construct containing a triplet of binding sites 
for the SR protein SF2/ASF (5’-AGAAGAACAAGAAGAACAAGAAGAACG-3’).  
Transient transfection and RT-PCR analysis. The different pcDNA-Dup constructs have been 
transiently transfected into HeLa cells, as described above. Cells were harvested 24 h post-
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transfection and total RNA was extracted using the TriPure Isolation Reagent (Roche Applied 
Science). The RNA preparations were treated by Amplification Grade DNase I (AMP-D1, 
Sigma-Aldrich), according to the manufacturer’s instructions and subjected to RT-PCR 
analysis. The one-step RT-PCR reaction was performed from 0.5 µg DNase-treated RNA in a 
25 µl reaction volume using the OneStep RT-PCR kit (Qiagen), according to the 
manufacturer’s instructions. Reverse transcription was done using the reverse primer Dup-2R 
(5’-GGACTCAAAGAACCTCTGGG-3’) that binds to the last exon of the minigene and PCR 
amplification was performed with 25 cycles using the forward primer T7-Pro (5’-
TAATACGACTCACTATAGGG-3’), which binds immediately upstream of the Dup 
minigene, and Dup-2R. RT-PCR products were separated by electrophoresis on 2.5% agarose 
gel containing ethidium bromide and visualized by exposure to ultraviolet light. Each DNA 
band was extracted from the gel by using Nucleospin Extract II kit (Macherey-Nagel) and 
sequenced using Big dye Terminator cycle sequencing kit (Applied Biosystems) on an 
automated sequencer (ABI 3130, Applied Biosystems). 
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RESULTS 
Identification of the BRCA1 c.5434C>G variant in an ovarian cancer patient 
The patient was referred for genetic counseling, based on the diagnosis of ovarian cancer at 
53 years and her family history. Her mother and maternal aunt were diagnosed with ovarian 
cancer at ages 53 and 65 years, respectively. Her paternal aunt was diagnosed with breast 
cancer at age 65 years. Using the Manchester scoring system,[15] prior probabilities of a 
pathogenic mutation were 51% in the BRCA1 gene and 32% in the BRCA2 gene. Based on 
this information, the genomic DNA of this patient was screened for germ-line mutations and 
large genomic rearrangements in both BRCA1 and BRCA2 genes. No genetic alteration was 
found in BRCA2. However, a C to G transvertion was identified at position c.5434 of BRCA1. 
At the time of genetic counseling, this BRCA1 c.5434C>G variant was not listed in the 
BRCA1 mutation BIC database nor in the French database of BRCA1 mutation (Dr. Rosette 
Lidereau, personal communication). It was therefore considered as an unclassified variant. In 
order to assess the pathogenicity of this variant, partial segregation analysis was performed. 
As the mother of the proband was deceased at the time of the analysis, her affected maternal 
aunt was tested and found to be a carrier of BRCA1 c.5434C>G. This observation suggested a 
germline transmission of the variant in the maternal branch, indicating that it could represent 
the disease causing mutation or a genetic marker linked to it. 
 
The BRCA1 c.5434C>G variant is associated with abnormal splicing of BRCA1 mRNA 
in patient blood cells 
In order to evaluate the consequence of the BRCA1 c.5434C>G sequence variant on BRCA1 
pre-mRNA splicing, RT-PCR analysis was performed using total RNA extracted from 
peripheral lymphocytes of the proband and a control subject (Fig. 1A). A single product with  
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the expected size (456 bp) was detected in the control subject and sequencing confirmed that 
it corresponds to the region covering exon 20 to the 3’UTR of the normal BRCA1 transcript, 
including exon 23 (Fig. 1A). In contrast, the analysis of RNA from the patient carrying the 
BRCA1 c.5434C>G variant revealed the presence of an additional RT-PCR product with a 
smaller size (395 bp), expressed at a slightly lower level, that was identified by sequencing as 
an aberrant transcript lacking BRCA1 exon 23 (Fig. 1A). Semi-quantitative analysis indicated 
that this RT-PCR product accounts for 35% of the total transcripts (data not shown). 
Therefore, skipping of exon 23 in the transcript corresponding to the mutant allele could be 
incomplete, or the aberrant mRNA could be degraded in part by the NMD pathway. 
Sequencing of the top band corresponding to the normal BRCA1 transcript showed a barely 
detectable signal from the mutant sequence, strongly suggesting that very low levels of 
normal mRNA were expressed from the mutant allele. This result demonstrates that the 
presence of the BRCA1 c.5434C>G variant is associated with a major splicing defect, 
resulting in the skipping of exon 23. 
 
The BRCA1 c.5434C>G variant induces BRCA1 exon 23 skipping in a minigene splicing 
assay 
In order to test the hypothesis that this aberrant skipping of BRCA1 exon 23 was directly 
caused by the substitution C to G at position c.5434, the effect of the variant on splicing was 
assessed using a minigene splicing assay (Fig. 1B).  pCAS minigene constructs carrying either 
the wild-type or the mutant BRCA1 c.5434C>G exon 23 were transiently expressed in HeLa 
cells and the minigene transcripts were analyzed by RT-PCR (Fig. 1C). Because the patient is 
heterozygous for the frequent SNP c.5407-193A>G (rs8176310, minor allele frequency:  
0.456) located in intron 22, the wild-type and mutant c.5434C>G minigene constructs carried 
the G and A polymorphic nucleotides, respectively. All the processed RNA expressed from 
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the wild-type BRCA1 exon 23 minigene retained BRCA1 exon 23, indicating that the less 
frequent G nucleotide at the intronic polymorphism rs8176310 has no negative effect on 
splicing. In contrast, the major spliced transcript expressed from the mutant BRCA1 
c.5434C>G exon 23 minigene exhibits skipping of exon 23 (Fig. 1C). Semi-quantitative 
analysis indicated that, in this monoallelic assay, 75% of the total transcripts have skipped 
exon 23 (data not shown). These data demonstrate that the variant BRCA1 c.5434C>G is 
directly responsible for a major splicing defect. 
  
The BRCA1 region c.5420-5449 in the centre of exon 23 contains sequences with global 
enhancer properties, which are affected by the c.5434C>G mutation 
The c.5434C>G variant is located in the centre (position +28) of the short exon 23 (61 bp) of 
the BRCA1 gene, in a region highly conserved at nucleotide level across species (Fig. 2). 
Nucleotide sequence conservation is particularly striking in a stretch of 6 amino acids with 
highly degenerate codons (IVVVQP). Such an exonic mutation, associated with exon 
skipping and located at distance from the splice sites, is likely to affect splicing regulatory 
elements. In order to determine if the BRCA1 exonic region affected by the c.5434C>G 
mutation contains a splicing enhancer element (ESE), we took advantage of an ESE-
dependent splicing assay (Fig. 3A).[12] A ~30 bp fragment was inserted into the middle exon 
of a three-exon minigene under the control of a CMV promoter. The different minigenes were 
transiently expressed in HeLa cells and the splicing patterns of the minigene transcripts were 
analyzed by RT-PCR. Due to a weak 3’ splice site, this middle exon is not recognized by the 
splicing machinery and therefore is excluded from the processed transcript, unless enhancer 
elements are inserted within its sequence.[12] As expected, the middle exon was included into 
the mature transcripts expressed from a positive control minigene (SF2/ASF-3x) carrying 
triplet of enhancer elements (ESE), known to bind to the splicing regulatory SR protein 
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SF2/ASF (Fig. 3B), whereas the middle exon without enhancer element was excluded from 
the mature transcripts expressed from minigenes without an inserted sequence (empty), or 
containing a randomly chosen intronic sequence derived from the BRCA2 intron 11 
(BR2Int11) (Fig. 3B).  The wild-type c.5420-5449 segment of BRCA1 exon 23 was able to 
induce inclusion of the middle exon (Fig. 3B), strongly suggesting that this specific region 
contains a sequence with enhancer properties. In contrast, the middle exon was excluded from 
the mature transcripts expressed from the minigene carrying the BRCA1 exon 23 c.5420-5449 
region with the c.5434C>G mutation. This result indicates that the c.5434C>G variant induces 
skipping of BRCA1 exon 23 either by disrupting an enhancer element (ESE) or by creating a 
silencer element (ESS).  
We also analyzed the impact on splicing of a reported SNP at the same position (BRCA1 
c.5434C>T; rs1800751) by using the same ESE-dependent assay (Fig. 3B). In contrast to the 
c.5434C>G mutation, the c.5434C>T variant had modest negative effect on the inclusion of 
the middle exon. This result suggests that the effect on splicing at position c.5434 is 
nucleotide-dependent. 
Both exonic variants, BRCA1 c.5434C>G and c.5434C>T, were analyzed by using 
bioinformatics prediction programs, for possible splicing enhancer (ESE) disruption and 
silencer (ESS) creation. As shown in Table 1, ESEfinder predicts that both nucleotide changes 
destroy a SF2/ASF enhancer element and decrease the score or destroy an ESE motif for 
SRp55. Interestingly, Human Splicing Finder predicts that only the c.5434C>G variant would 
create a silencer element for hnRNPA1 (Table 1), motif identified using an experimental 
matrix recently designed for this splicing factor.[11]   
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Table 1. Bioinformatics predictions of splicing regulatory elements   
Linked 
SR / hnRNP 
Protein 
ESE / ESS 
Motif 
Threshold 
Wild-Type 
Sequencec (Score) 
Mutant c.5434C>G 
Sequencec (Score) 
Mutant c.5434C>T 
Sequencec (Score) 
SF2/ASFa 1.956 CAGCCAG (2.04) CAGGCAG (0*) CAGTCAG (0*) 
SRp55a 2.676 TGCAGC (4.71) TGCAGG (2.95) TGCAGT (0*) 
hnRNPA1b 65.476 CAGCCAG (0) CAGGCAG (74.76*) CAGTCAG (0) 
a
, as determined using ESE finder [8, 9] 
b
, as determined using hnRNPA1 experimental motif from HSF [11] 
c
, the nucleotide underlined indicates the position of the mutation 
*, scores that differ significantly considering the threshold 
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DISCUSSION 
We have shown, using patient RNA analyses and minigene splicing assays, that the BRCA1 
variant c.5434C>G (p.Pro1812Ala) induces a major splicing defect, resulting in the skipping 
of exon 23. The amount of exon skipping was estimated at 75% in the monoallelic splicing 
minigene assay, a value that is consistent with the analysis of RT-PCR products obtained from 
patient blood cell RNA. Translation of the aberrant transcript is predicted to result in a protein 
with a premature stop codon, p.Gly1803GlnfsX11, which disrupts the second BRCT domain. 
This functional region is essential for the tumor suppressor activity of the BRCA1 protein, as 
it is involved in DNA repair and transcriptional control.[16,17] Altogether, these results 
strongly suggest that the mutation BRCA1 c.5434C>G induces the production of a non-
functional protein, as a consequence of exon 23 skipping, and argue for its classification as a 
pathogenic mutation. This study adds to the growing list of examples indicating that missense 
changes, even those affecting extremely conserved amino-acid residues located in functional 
domains, should not be evaluated exclusively at protein level.[18] 
Over the past ten years, exonic mutations identified in genetic screening of several 
genes have been shown to induce exon skipping by altering splicing regulatory elements.[3] 
But, so far, in the BRCA1 gene, only two mutations, both located in exon 18, have been 
shown experimentally to affect splicing regulatory elements: the nonsense variant c.5080G>T 
(p.Glu1694X) [19-21] and the missense variant c.5123C>T (p.Ala1708Glu).[22] We 
investigated the mechanism underlying the effect of the mutation BRCA1 c.5434C>G on 
splicing. Using an ESE-dependent splicing assay, we show that the central 30 nucleotide-long 
region of exon 23 encloses a sequence with global enhancer properties, which are strongly 
affected by the c.5434C>G mutation. In contrast, the c.5434C>T variant, which corresponds 
to a SNP without allele frequencies listed in the dbSNP database of NCBI, has little effect in 
the ESE-dependent splicing assay and its functional consequences are debated.[23] The 
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bioinformatics predictions shown in Table I indicate, for both variants, a strong reduction of 
scores for two ESE elements and predict, only for the c.5434C>G variant, the generation of a 
new hnRNPA1 splicing silencer motif. Our data and these bioinformatics predictions suggest 
that the exonic variant BRCA1 c.5434C>G creates a sequence with silencer properties, 
predicted to bind the splicing repressor hnRNPA1. A similar model has been proposed to 
explain the impact on splicing of the nonsense BRCA1 c.5080G>T mutation, which causes 
exon 18 skipping [19] and was initially predicted to disrupt a splicing enhancer element for 
the SF2/ASF protein.[20] It has recently been shown that this variant creates a silencer 
element, which interacts with the inhibitory splicing factor hnRNPA1/A2 and DAZAP1.[21] 
The other variant in exon 18 of BRCA1 reported to induce exon skipping is the missense 
variant c.5123C>A, which is thought to increase the RNA binding of the splicing repressors 
hnRNPA1 and hnRNPH/F.[22] Similar models could explain the effect on exon 23 splicing of 
the BRCA1 c.5434C>G mutation. However, at this point, we cannot rule out other models, 
based on the inactivation of an ESE or on a combination of ESE inactivation and generation 
of an ESS. In the BRCA2 gene, exon skipping has been associated with the missense 
mutations c.8165C>G (p.Thr2722Arg) in exon 18 [24] and c.6853A>G (p.Ile2285Val) in 
exon 12 [25], but the molecular bases of these splicing defects have not been described. 
Retrospectively, one may ask if bioinformatics predictions could have pointed to the 
c.5434C>G variant as a splicing mutation. It should be noted that we initially decided to 
examine the effect of this variant on splicing not because of bioinformatics predictions, but 
because the available information on the functional consequences of this change at the protein 
level were inconclusive and family data suggested that it was directly or indirectly associated 
with the predisposition to breast/ovarian cancer.[6, and the present study] Most published 
evaluations of bioinformatics predictions of splicing defects deal with UVs that affect splice 
site changes, either by affecting 5’ or 3’ splice sites, or by creating or activating cryptic splice 
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sites. These predictions are usually considered sensitive and rather specific.[26] On the other 
hand, bioinformatics predictions of the effects of UVs on exonic regulatory elements are 
much less reliable and lack specificity.[12, 27, 28] Therefore, bioinformatics analyses of 
exonic splicing regulatory elements need the addition of other criteria to improve specificity. 
Strong sequence conservation at the nucleotide level could be among such additional criteria, 
as already suggested.[29, 30] Moreover, sequence variations in small size exons could be 
more prone to affect exonic splicing regulatory elements than those located in large size 
exons, [31] where compensatory effects may exist.  
In summary, our results provide in vivo and ex vivo evidences that the BRCA1 
c.5434C>G variant is pathogenic through a major skipping of exon 23. As is often the case 
with splicing mutations, the resulting defect is not complete, but was estimated to be present 
on about 75% of the transcripts from the mutant allele. This finding and the predicted 
deleterious consequences on the corresponding BRCA1 protein, together with segregation 
data from this family and from another family [6] places the c.5434C>G variant of BRCA1 
into class 4, i.e. “Likely pathogenic” of the classification system that has been recently 
proposed by Plon et al. [32]  
In addition, analyses of the effect of this variant on exonic splicing regulatory 
elements contribute to a better understanding of the mechanisms underlying splicing 
regulation. 
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KEY POINTS: 
• The variant BRCA1 c.5434C>G (p.Pro1812Ala) was found to induce a major splicing 
defect, resulting in exon 23 skipping in hybrid minigene assays and in blood cells from 
an ovarian cancer patient, arguing for its classification as a likely pathogenic splicing 
mutation. 
• The central segment c.5420-5449 of BRCA1 exon 23 exhibits splicing enhancer 
properties, which are abolished by the c.5434C>G mutation. 
• Bioinformatics analyses predict that the mutation BRCA1 c.5434C>G creates an 
hnRNPA1-dependent splicing silencer motif.  
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LEGENDS OF THE FIGURES 
Figure 1. The BRCA1 c.5434C>G variant induces aberrant splicing of exon 23 
A. RT-PCR analysis of BRCA1 transcript from patient blood cell RNA. Lane C: a control 
subject who does not carry the variant. Lane P: the ovarian cancer patient, carrier of the 
variant BRCA1 c.5434C>G. Ex20-3’UTR: transcript encompassing BRCA1 exon 20 to the 
3’UTR region; ∆Ex23: transcript with deletion of exon 23. Each RT-PCR has been repeated 
twice, and 2 control subjects have been tested in parallel, with reproducible results.  
 
B. Schematic representation of the pCAS minigene used in the functional splicing assay. 
Wild-type and mutant (c.5434C>G) exon 23 of BRCA1 (dark grey box) together with the 5’ 
and 3’ intronic flanking sequences (thick lines) are cloned into the pCAS minigene, using the 
BamHI and MluI restriction sites.[12] This plasmid is a pcDNA3.1-based vector that contains 
2 exons derived from SERPING1/CINH gene (white boxes), separated by their natural intron 
(thin line). Transcription is driven by the human cytomegalovirus immediate-early 
promoter/enhancer (CMV, large black arrow). The location of the primers (F and R) used for 
the RT-PCR analyses are represented by arrows.  
 
C. RT-PCR analysis of the spliced transcripts expressed from the BRCA1 exon 23 wild-type 
and mutant (c.5434C>G) pCAS minigene constructs. HeLa cells were transfected with 
different pCAS minigene constructs: without insert (pCAS vector), carrying BRCA1 exon 23 
wild-type (wt) or mutant (c.5434C>G). Total RNA was collected 24 hr after transfection and 
subjected to RT-PCR analysis. RT-PCR products were analyzed by ethidium bromide agarose 
gel separation followed by sequencing of the different bands. The inclusion or the exclusion 
of BRCA1 exon 23 (dark grey box) in each transcript is schematically indicated on the right. 
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Figure 2. The central region of BRCA1 exon 23 is highly conserved at the nucleotide 
level  
The upper panel shows a multiple nucleotide alignment of BRCA1 exon 23 across species. 
The location of the mutation c.5434C>G is indicated by an arrow, in the boxed codon of 
Proline 1812. The lower panel shows the corresponding amino acid alignment, with the 
position of Proline 1812 indicated by an arrow. The nucleotide segment (c.5420-5449) of 
BRCA1 exon 23 that has been analyzed in the ESE-dependent splicing assay shown in Figure 
3 is indicated by a straight line.  
 
 
Figure 3. The c.5420-5449 region of BRCA1 exon 23 contains sequences with global 
splicing enhancer properties, which are affected by the c.5434C>G mutation 
A. Schematic representation of the pcDNA-Dup minigene used in the ESE-dependent splicing 
assay. The plasmid pcDNA-Dup has a pcDNA3.1(-) backbone and a β-globin-derived three-
exon minigene (whites boxes and dark grey box) under the control of the CMV promoter 
(large black arrow).[12] The middle exon (dark grey box) is flanked upstream and 
downstream by the 130 nucleotides of human β-globin intron 1 (thin line). The sequences of 
the intron-exon boundaries of the middle exon are shown, with intronic and exonic sequences 
indicated in lower and upper case, respectively. The BRCA1 exon 23 (c.5420-5449) wild-type 
sequence (light grey box) was inserted into the EcoRI and BamHI sites (underlined) of the 
minigene middle exon, as indicated by the broken lines. The location of the primers (F and R) 
used for the RT-PCR analyses are represented by arrows.  
 
B. ESE-dependent splicing assay. RT-PCR analysis of the spliced transcripts expressed from 
the pcDNA-Dup constructs carrying BRCA1 exon 23 c.5420-5449 fragments either wild-type 
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(wt) or mutant (c.5434C>G and c.5434C>T). In parallel, negative controls with the pcDNA-
Dup empty vector (empty) or a pcDNA-Dup construct containing a fragment of the BRCA2 
intron 11 (BR2Int11), as well as a positive control with a pcDNA-Dup containing triplet of 
binding sites for the SR protein SF2/ASF (SF2/ASF-3x) were carried out. Spliced transcripts 
were analyzed on a 2.5% agarose gel and visualized by ethidium-bromide staining. The 
inclusion or the exclusion of the middle exon (dark grey box) in each transcript is 
schematically indicated on the right. 
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